|
Three CAB members, 3 staff members and 2 guests attended the October 2003 meeting of the UTMB Galveston AIDS Clinical Trials Unit Community Advisory Board (CAB).
Dr.
Roberts opened the meeting with a report on the site's PI search:
· Dr. David Wolf, PI candidate from Univ. of North Carolina - Chapel Hill, visited the site and was impressed by the staff and the site's improved performance, in spite of not having a permanent PI.
Report
from Carrie:
· There are currently 12 ACTU intervention studies and 2 observational studies open to accrual. A5163, a bone density study that was pending last month is now open for accrual.
· A5157, an interventional protocol to study the treatment of peripheral neuropathy with L-Carnitine is still pending.
· Discussion and planning for ACTU/CAB outreach efforts will be a part of the monthly CAB meetings. Separate outreach meeting will be called for particular outreach events.
·
The CAB
mailing list is being updated to keep it current. The option to receive CAB-related notices via email or snail
mail will be offered. Please
respond when you receive the form requesting this information.
Member's
news:
· Members present at this meeting voted a new CAB member in.
·
The CAB will
not meet in December.
Guest
speaker, Sidney Bailey, RN, BSN, CDE, from UTMB's Stark Diabetes Center gave an
informative presentation on the complications of diabetes and HIV.
Highlights:
· Types of diabetes: Type I (insulin-dependent or juvenile onset), Type II (noninsulin-dependent or maturity onset), gestational (occurring during pregnancy) and secondary (related to HIV/antiretroviral medications, chemotherapy, or use of steroids).
· Prevalence: 17 million people (6.2% of the population). From 1990 to 2000 the prevalence has increased 5 fold.
· Deaths from diabetes: In 1999 approximately 450,000 people 25 years and older. The overall risk of death is 2 times greater for diabetics.
· Diabetes and HIV: It remains unclear if HIV and its treatment are associated with the risk of diabetes vs. the fact that people with HIV are living longer and developing age related complications such as diabetes. Studies have demonstrated glucose intolerance and insulin resistance in HIV patients taking PIs as well as HIV negative controls taking PIs.
Back to CAB Minutes 2003
|
|